Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2020) 70 EP218 | DOI: 10.1530/endoabs.70.EP218

ECE2020 ePoster Presentations Diabetes, Obesity, Metabolism and Nutrition (142 abstracts)

Dynamics of indicators of cytolysis, carbonyl stress in patients with type 2 diabetes and non-alcoholic fatty liver disease on glucose-lowering therapies

Rodionova Svetlana , Zvenigorodskaya Larissa , Biryukova Elena , Petrakov Alexander & Nilova Tamara


Moscow Clinical Research Center Named After Loginov, Moscow, Russian Federation


Objective: To study the dynamics of cytolysis and carbonyl stress (methylglyoxal (MG)) in patients with type 2 diabetes mellitus (DM2) and non-alcoholic fat disease liver (NAFLD) on the background of various hypoglycemic therapy.

Materials and methods: The study included 48 patients, 53.8 ± 11.14 years, with SD2 and NAFLD and 20 people in the control group. Viral hepatitis was excluded, toxic and drug-induced liver injury. Anthropometric researc included: determination of waist circumference, body weight, height, and index calculation body mass index (BMI). Indicators of cytolysis (ALT, AST) and carbonyl stress were evaluated. Patients were divided into 2 groups: 1) inhibitors sodium-glucose cotransporter type 2 + Metformin (MF); 2) preparations sulfonylureas (PSU) + MF.

Results: The BMI was 35.8 ± 8.67 kg/2 on average for the group, from 109.5 ± 16.48 sm, which indicated abdominal type of obesity. In patients with DM2 and NAFLD, a higher concentration of MG was detected, compared with the the control group. the following dynamics of indicators: in the first group (I-NGL-2 + MF) before BMI treatment was 35.1 ± 6.66, after 12 months 33.8 ± 6.95, in the second group ((PSM) + MF) 36.48 ± 7.66; 39.26 ± 7.64, respectively, the level of glycated hemoglobin (HbA1c): I-NGLT-2 + MF: before treatment 8.18 ± 1.52, after 12 months 7.37 ± 1.76, (PSM) + MF: 8.51 ± 1.58; 8.65 ± 1.14 accordingly, ALT level: I-NGL-2 + MF: before treatment 72.95 ± 58.79, after 12 months 29.42 ± 18.27, (PSM) + MF: 39.29 ± 45.89; 36.26 ± 23.97, respectively. After 12 month of treatment, In the first group, there was more pronounced weight loss, HbA1c, ALT, MG, as a product of excessive glycosylation, carbonyl stress index.

Conclusions: Based on the results of the preliminary analysis, we can say that inhibitors sodium-glucose cotransporter type 2 + Metformin (MF) are more preferable in comparison with PSU in combination with MF, in these patients.

Volume 70

22nd European Congress of Endocrinology

Online
05 Sep 2020 - 09 Sep 2020

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.